PubMed Journals Articles About "Reader Inquiry Krystal Biotech Participating Rally Gene Therapy" RSS

09:11 EDT 15th October 2018 | BioPortfolio

Reader Inquiry Krystal Biotech Participating Rally Gene Therapy PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Reader Inquiry Krystal Biotech Participating Rally Gene Therapy articles that have been published worldwide.

More Information about "Reader Inquiry Krystal Biotech Participating Rally Gene Therapy" on BioPortfolio

We have published hundreds of Reader Inquiry Krystal Biotech Participating Rally Gene Therapy news stories on BioPortfolio along with dozens of Reader Inquiry Krystal Biotech Participating Rally Gene Therapy Clinical Trials and PubMed Articles about Reader Inquiry Krystal Biotech Participating Rally Gene Therapy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Reader Inquiry Krystal Biotech Participating Rally Gene Therapy Companies in our database. You can also find out about relevant Reader Inquiry Krystal Biotech Participating Rally Gene Therapy Drugs and Medications on this site too.

Showing "Reader Inquiry Krystal Biotech Participating Rally Gene Therapy" PubMed Articles 1–25 of 23,000+

Gene therapy for visual loss: Opportunities and concerns.

Many clinical trials using gene therapy have shown significant therapeutic benefits and exceptional safety records. Increasing evidence is verifying the long sought-after promise that gene therapy will genetically 'cure' some severely disabling diseases. In particular, the first gene therapy bioproduct for RPE65-associated Leber's congenital amaurosis, which was approved by the US Food and Drug Administration in 2017, has provided tremendous encouragement to the field of gene therapy. Recent developments in...

Immune Gene Therapy and the International Conference on Lymphocyte Engineering (ICLE 2018).

An important step on the long path to clinical application of in utero gene therapy.

Future AAVenues for In Utero Gene Therapy.

Fetal gene therapy using safe and effective viral vectors no longer remains a distant prospect. Recently in Nature Medicine, Massaro et al. (2018) demonstrated that prenatal intracranial injection of a viral vector results in improved neurologic function, raising the intriguing possibility that in utero gene therapy may be approaching clinical applications.

Lessons learned from lung and liver in-vivo gene therapy: implications for the future.

Ex-vivo gene therapy has had significant clinical impact over the last couple of years and in-vivo gene therapy products are being approved for clinical use. Gene therapy and gene editing approaches have huge potential to treat genetic disease and chronic illness. Areas covered: This article provides a review of in-vivo approaches for gene therapy in the lung and liver, exploiting non-viral and viral vectors with varying serotypes and pseudotypes to target specific cells. Antibody responses inhibiting viral...

Airway Basal Cells Are the Key for Cystic Fibrosis Gene Therapy.

Effective gene therapy for hemophilia, at last….

Recent efforts at gene therapy for haemophilia A and B using AAV-derived vectors show durable expression of coagulation factors at significant levels, resulting in almost complete correction of the phenotype. This is the first success of gene therapy for a major hereditary disorder, and shows how continuous improvement of many components of the system has finally succeeded. Although these results must be confirmed with more patients and longer durations, they constitute a significant accomplishment for this...

Correction to: Recent Progress on Genetic Diagnosis and Therapy for β-Thalassemia in China and Around the World, by Zhang J, Yan J, and Zeng F. Hum Gene Ther 2018;29(2):197-203. DOI: 10.1089/hum.2017.228.


Choroideremia (CHM) is a rare inherited retinal degeneration resulting from mutation of the CHM gene, which results in absence of functional Rab escort protein 1 (REP1). We evaluated retinal gene therapy with an adeno-associated virus vector that used to deliver a functional version of the CHM gene (AAV2-REP1).

Gene therapy in optic nerve disease.

Highlight some of the recent advances in gene therapy and gene modification for optic nerve disease to promote axon regeneration, neuroprotection, and increased visual functioning.

Gene Therapy Briefs.

British Society for Gene and Cell Therapy Annual Conference Friday 27 April 2018 Regent's Conference Centre, London, UK

Diabetic complication could get a gene therapy boost.

Comparison of the editing patterns and editing efficiencies of TALEN and CRISPR-Cas9 when targeting the human CCR5 gene.

The human C-C chemokine receptor type-5 (CCR5) is the major transmembrane co-receptor that mediates HIV-1 entry into target CD4+ cells. Gene therapy to knock-out the CCR5 gene has shown encouraging results in providing a functional cure for HIV-1 infection. In gene therapy strategies, the initial region of the CCR5 gene is a hotspot for producing functional gene knock-out. Such target gene editing can be done using programmable endonucleases such as transcription activator-like effector nucleases (TALEN) or...

Disease-modifying Osteoarthritis Treatment with Interleukin-1 Receptor Antagonist Gene Therapy in Small and Large Animal Models.

Gene therapy holds great promise for the treatment of osteoarthritis (OA) because a single intraarticular injection can lead to long-term expression of therapeutic proteins within the joint. Here we report the development of a helper-dependent adenovirus (HDAd)-mediated intraarticular gene therapy approach for long-term expression of interleukin-1 receptor antagonist (IL-1Ra) for sustained symptomatic and disease-modifying OA therapy.

Gene Therapy and Virotherapy of Gliomas.

Despite many recent advances in the management of gliomas, such as aggressive surgical resection, chemoradiotherapy, antiangiogenic therapy, and molecular targeted therapy, the survival of patients with high-grade neoplasms remains dismal. Gene therapy and oncolytic virotherapy have emerged as highly promising strategies for treatment of malignant brain tumors due to recent progress in understanding of the underlying cancer biology as well as improved techniques for genetic modification of potential therape...

Relationship between Roe and Metz simulation model for multireader diagnostic data and Obuchowski-Rockette model parameters.

For the typical diagnostic radiology study design, each case (ie, patient) undergoes several diagnostic tests (or modalities) and the resulting images are interpreted by several readers. Often, each reader is asked to assign a confidence-of-disease rating to each case for each test, and the diagnostic tests are compared with respect to reader-performance outcomes that are functions of the reader receiver operating characteristic (ROC) curves, such as the area under the ROC curve. These reader-performance ou...

Activity-Induced Regulation of Synaptic Strength through the Chromatin Reader L3mbtl1.

Homeostatic synaptic downscaling reduces neuronal excitability by modulating the number of postsynaptic receptors. Histone modifications and the subsequent chromatin remodeling play critical roles in activity-dependent gene expression. Histone modification codes are recognized by chromatin readers that affect gene expression by altering chromatin structure. We show that L3mbtl1 (lethal 3 malignant brain tumor-like 1), a polycomb chromatin reader, is downregulated by neuronal activity and is essential for sy...

Progress in gene therapy using oncolytic vaccinia virus as vectors.

Vaccinia virus was widely used in the World Health Organization's smallpox eradication campaign and is currently a promising vector for gene therapy owing to its unique characteristics. Vaccinia virus can selectively replicate and propagate productively in tumor cells, resulting in oncolysis. In addition, rapid viral particle production, wide host range, large genome size (approximately 200 kb), and safe handling render vaccinia virus a suitable vector for gene therapy.

Branch-PCR constructed TP53 gene nanovector for potential cancer therapy.

A novel and efficient branch PCR strategy has been used to construct a TP53 gene nanovector based on a pair of trimers as primers, which showed unique advantages compared to other existing systems for gene delivery and effective potential cancer therapy.

The Blunt End: Surgical Challenges of Gene Therapy for Inherited Retinal Diseases.

Review barriers to effective transduction of cells in the subretinal plane during gene therapy surgery for inherited retinal dystrophies (IRD).

Socioeconomic status of parents with children participating on youth club sport teams.

To describe the socioeconomic status, measured by household income and educational attainment, of parents with children participating on youth club sport teams.

Gene therapy in inherited retinal degenerative diseases, a review.

Hereditary diseases of the retina represent a group of diseases with several heterogeneous mutations that have the common end result of progressive photoreceptor death leading to blindness. Retinal degenerations encompass multifactorial diseases such as age-related macular degeneration, Leber congenital amaurosis, Stargardt disease, and retinitis pigmentosa. Although there is currently no cure for degenerative retinal diseases, ophthalmology has been at the forefront of the development of gene therapy, whic...

Improved molecular platform for the gene therapy of rare diseases by liver protein secretion.

Many rare monogenic diseases are treated by protein replacement therapy, in which the missing protein is repetitively administered to the patient. However, in several cases, the missing protein is required at a high and sustained level, which renders protein therapy far from being adequate. As an alternative, a gene therapy treatment ensuring a sustained effectiveness would be particularly valuable. Liver is an optimal organ for the secretion and systemic distribution of a therapeutic transgene product. Cut...

Gene Therapy for Retinal Degeneration.

Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. To view this Bench to Bedside, open or download the PDF.

Quick Search